PainReform Ltd. announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8001 USD | -6.31% | +0.01% | -70.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.91% | 2.11M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- PRFX Stock
- News PainReform Ltd.
- PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy